you are here:

Eris Lifesciences Ltd.

BSE: 540596 | NSE: ERIS |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE406M01024 | SECTOR: Pharmaceuticals & Drugs

BSE Live

Aug 04, 11:13
761.90 -6.55 (-0.85%)
Volume
AVERAGE VOLUME
5-Day
31,071
10-Day
22,859
30-Day
18,434
4,727
  • Prev. Close

    768.45

  • Open Price

    772.55

  • Bid Price (Qty.)

    761.00 (151)

  • Offer Price (Qty.)

    761.50 (7)

NSE Live

Aug 04, 11:14
761.15 -6.50 (-0.85%)
Volume
AVERAGE VOLUME
5-Day
371,108
10-Day
248,509
30-Day
229,700
31,297
  • Prev. Close

    767.65

  • Open Price

    771.70

  • Bid Price (Qty.)

    761.00 (61)

  • Offer Price (Qty.)

    761.15 (17)

Financials

2020 2019 2018 2017 2016
Nine Months Results of Eris Lifesciences (in Rs. Cr.) Dec '20 Dec '19 Dec '18 Dec '17 Dec '16  
Net Sales/Income from operations 835.97 777.68 686.52 566.53 545.78  
Other Operating Income 16.02 11.82 11.59 -- --  
Total Income From Operations 851.99 789.49 698.11 566.53 545.78  
EXPENDITURE  
Consumption of Raw Materials 77.34 52.86 46.64 34.56 38.33  
Purchase of Traded Goods 81.83 59.33 58.08 48.17 43.91  
Increase/Decrease in Stocks -10.73 19.26 -2.72 -2.92 1.53  
Power & Fuel -- -- -- -- --  
Employees Cost 160.67 140.73 125.73 95.15 88.85  
Depreciation 27.50 31.92 21.55 14.02 15.64  
Excise Duty -- -- -- -- --  
Admin. And Selling Expenses -- -- -- -- --  
R & D Expenses -- -- -- -- --  
Provisions And Contingencies -- -- -- -- --  
Exp. Capitalised -- -- -- -- --  
Other Expenses 219.58 234.96 198.64 147.85 157.49  
P/L Before Other Inc. , Int., Excpt. Items & Tax 295.79 250.44 250.19 229.70 200.04  
Other Income 7.25 15.53 20.90 20.02 18.36  
P/L Before Int., Excpt. Items & Tax 303.04 265.97 271.08 249.72 218.40  
Interest 0.58 1.59 18.41 2.71 0.74  
P/L Before Exceptional Items & Tax 302.46 264.38 252.67 247.01 217.66  
Exceptional Items -- -- -- -- --  
P/L Before Tax 302.46 264.38 252.67 247.01 217.66  
Tax 21.21 28.21 19.71 10.86 22.02  
P/L After Tax from Ordinary Activities 281.26 236.17 232.97 236.16 195.64  
Prior Year Adjustments -- -- -- -- --  
Extra Ordinary Items -- -- -- -- --  
Net Profit/(Loss) For the Period 281.26 236.17 232.97 236.16 195.64  
Equity Share Capital 13.58 13.75 13.75 13.75 13.75  
Reserves Excluding Revaluation Reserves -- -- -- -- --  
Equity Dividend Rate (%) -- -- -- -- --  
EPS Before Extra Ordinary  
Basic EPS 20.71 17.17 16.94 17.18 14.23  
Diluted EPS 20.69 17.15 16.93 17.18 14.23  
EPS After Extra Ordinary  
Basic EPS. 20.71 17.17 16.94 17.18 14.23  
Diluted EPS. 20.69 17.15 16.93 17.18 14.23  
Public Share Holding  
No Of Shares (Crores) -- -- -- -- --  
Share Holding (%) -- -- -- -- --  
Promoters and Promoter Group Shareholding  
a) Pledged/Encumbered  
- Number of shares (Crores) -- -- -- -- --  
- Per. of shares (as a % of the total sh. of prom. and promoter group) -- -- -- -- --  
- Per. of shares (as a % of the total Share Cap. of the company) -- -- -- -- --  
b) Non-encumbered  
- Number of shares (Crores) -- -- -- -- --  
- Per. of shares (as a % of the total sh. of prom. and promoter group) -- -- -- -- --  
- Per. of shares (as a % of the total Share Cap. of the company) -- -- -- -- --  
Source : Dion Global Solutions Limited

Results of Pharmaceuticals & Drugs Sector

No News.
No News.
No News.
No News.